Ilyang Pharmaceutical Co Ltd
KRX:007570
Ilyang Pharmaceutical Co Ltd
Income from Continuing Operations
Ilyang Pharmaceutical Co Ltd
Income from Continuing Operations Peer Comparison
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
I
|
Ilyang Pharmaceutical Co Ltd
KRX:007570
|
Income from Continuing Operations
-₩204.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Yuhan Corp
KRX:000100
|
Income from Continuing Operations
₩122.6B
|
CAGR 3-Years
9%
|
CAGR 5-Years
18%
|
CAGR 10-Years
4%
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Income from Continuing Operations
-₩35.4B
|
CAGR 3-Years
48%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Income from Continuing Operations
₩178.9B
|
CAGR 3-Years
83%
|
CAGR 5-Years
35%
|
CAGR 10-Years
13%
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Income from Continuing Operations
-₩3.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
C
|
Celltrion Pharm Inc
KOSDAQ:068760
|
Income from Continuing Operations
₩16.5B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
24%
|
See Also
What is Ilyang Pharmaceutical Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
-204.4m
KRW
Based on the financial report for Mar 31, 2024, Ilyang Pharmaceutical Co Ltd's Income from Continuing Operations amounts to -204.4m KRW.